Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Clinical spectrum of central nervous system myelin oligodendrocyte glycoprotein autoimmunity in adults.

Cobo-Calvo A, Vukusic S, Marignier R.

Curr Opin Neurol. 2019 Feb 11. doi: 10.1097/WCO.0000000000000681. [Epub ahead of print]

PMID:
30762607
2.

Correction to: Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults.

Cobo-Calvo A, Sepúlveda M, d'Indy H, Armangué T, Ruiz A, Maillart E, Papeix C, Audoin B, Zephir H, Biotti D, Ciron J, Durand-Dubief F, Collongues N, Ayrignac X, Labauge P, Thouvenot E, Montcuquet A, Deschamps R, Solà-Valls N, Llufriu S, Blanco Y, de Seze J, Vukusic S, Saiz A, Marignier R; OFSEP Group; REEM Group.

J Neurol. 2019 Feb 7. doi: 10.1007/s00415-019-09215-1. [Epub ahead of print]

PMID:
30759286
3.

Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).

Vukusic S, Brassat D, de Seze J, Izquierdo G, Lysandropoulos A, Moll W, Vanopdenbosch L, Arque MJ, Kertous M, Rufi P, Oreja-Guevara C.

Mult Scler Relat Disord. 2019 Jan 6;29:7-14. doi: 10.1016/j.msard.2019.01.019. [Epub ahead of print]

PMID:
30654246
4.

Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults.

Cobo-Calvo A, Sepúlveda M, d'Indy H, Armangué T, Ruiz A, Maillart E, Papeix C, Audoin B, Zephir H, Biotti D, Ciron J, Durand-Dubief F, Collongues N, Ayrignac X, Labauge P, Thouvenot E, Montcuquet A, Deschamps R, Solà-Valls N, Llufriu S, Blanco Y, de Seze J, Vukusic S, Saiz A, Marignier R; OFSEP Group; REEM Group.

J Neurol. 2019 Jan 3. doi: 10.1007/s00415-018-9160-9. [Epub ahead of print] Erratum in: J Neurol. 2019 Feb 7;:.

PMID:
30607536
5.

Multiple sclerosis with atypical MRI presentation: Results of a nationwide multicenter study in 57 consecutive cases.

Codjia P, Ayrignac X, Carra-Dalliere C, Cohen M, Charif M, Lippi A, Collongues N, Corti L, De Seze J, Lebrun C, Vukusic S, Durand-Dubief F, Labauge P; SFSEP and OFSEP.

Mult Scler Relat Disord. 2018 Dec 18;28:109-116. doi: 10.1016/j.msard.2018.12.022. [Epub ahead of print]

PMID:
30592992
6.

Observatoire Français de la Sclérose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France.

Vukusic S, Casey R, Rollot F, Brochet B, Pelletier J, Laplaud DA, De Sèze J, Cotton F, Moreau T, Stankoff B, Fontaine B, Guillemin F, Debouverie M, Clanet M; the OFSEP Investigators.

Mult Scler. 2018 Dec 13:1352458518815602. doi: 10.1177/1352458518815602. [Epub ahead of print]

PMID:
30541380
7.

Author Correction: Multiple sclerosis.

Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, Rocca MA.

Nat Rev Dis Primers. 2018 Nov 22;4(1):49. doi: 10.1038/s41572-018-0050-3.

PMID:
30467372
8.

Multiple sclerosis.

Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, Rocca MA.

Nat Rev Dis Primers. 2018 Nov 8;4(1):43. doi: 10.1038/s41572-018-0041-4. Review. Erratum in: Nat Rev Dis Primers. 2018 Nov 22;4(1):49.

PMID:
30410033
9.

Multiple sclerosis registries in Europe - An updated mapping survey.

Glaser A, Stahmann A, Meissner T, Flachenecker P, Horáková D, Zaratin P, Brichetto G, Pugliatti M, Rienhoff O, Vukusic S, de Giacomoni AC, Battaglia MA, Brola W, Butzkueven H, Casey R, Drulovic J, Eichstädt K, Hellwig K, Iaffaldano P, Ioannidou E, Kuhle J, Lycke K, Magyari M, Malbaša T, Middleton R, Myhr KM, Notas K, Orologas A, Otero-Romero S, Pekmezovic T, Sastre-Garriga J, Seeldrayers P, Soilu-Hänninen M, Stawiarz L, Trojano M, Ziemssen T, Hillert J, Thalheim C.

Mult Scler Relat Disord. 2019 Jan;27:171-178. doi: 10.1016/j.msard.2018.09.032. Epub 2018 Oct 4. No abstract available.

PMID:
30384204
10.

Where there is inflammation, treatment may reduce disability progression - No.

Edan G, Vukusic S.

Mult Scler. 2018 Oct 8:1352458518795417. doi: 10.1177/1352458518795417. [Epub ahead of print] No abstract available.

PMID:
30295565
11.

Objective Evaluation of Multiple Sclerosis Lesion Segmentation using a Data Management and Processing Infrastructure.

Commowick O, Istace A, Kain M, Laurent B, Leray F, Simon M, Pop SC, Girard P, Améli R, Ferré JC, Kerbrat A, Tourdias T, Cervenansky F, Glatard T, Beaumont J, Doyle S, Forbes F, Knight J, Khademi A, Mahbod A, Wang C, McKinley R, Wagner F, Muschelli J, Sweeney E, Roura E, Lladó X, Santos MM, Santos WP, Silva-Filho AG, Tomas-Fernandez X, Urien H, Bloch I, Valverde S, Cabezas M, Vera-Olmos FJ, Malpica N, Guttmann C, Vukusic S, Edan G, Dojat M, Styner M, Warfield SK, Cotton F, Barillot C.

Sci Rep. 2018 Sep 12;8(1):13650. doi: 10.1038/s41598-018-31911-7.

12.

"Myelitis migrans": A rare cause of treatable myelitis.

Jaulent P, Pegat A, Grosset-Janin C, Durand-Dubief F, Vukusic S, Marignier R.

Rev Neurol (Paris). 2018 Dec;174(10):745-747. doi: 10.1016/j.neurol.2017.12.005. Epub 2018 Aug 22. No abstract available.

PMID:
30143322
13.

Weekly enhanced T1-weighted MRI with Gadobutrol injections in MS patients: Is there a signal intensity increase in the dentate nucleus and the globus pallidus?

Jaulent P, Hannoun S, Kocevar G, Rollot F, Durand-Dubief F, Vukusic S, Brisset JC, Sappey-Marinier D, Cotton F.

Eur J Radiol. 2018 Aug;105:204-208. doi: 10.1016/j.ejrad.2018.06.011. Epub 2018 Jun 19.

PMID:
30017281
14.

Unusual neurologic presentation of aseptic abscesses syndrome.

Nicolas P, Guerrier O, Benoit A, Durand-Dubief F, Raverot G, Debarbieux S, Delteil C, Vasiljevic A, Jouanneau E, Cotton F, Marignier R, Vukusic S.

Neurol Neuroimmunol Neuroinflamm. 2018 Jun 5;5(4):e469. doi: 10.1212/NXI.0000000000000469. eCollection 2018 Jul. No abstract available.

15.

Efficacy of rituximab in refractory RRMS.

Durozard P, Maarouf A, Boutiere C, Ruet A, Brochet B, Vukusic S, Carra-Dalliere C, Labauge P, Mathey G, Debouverie M, Papeix C, Maillart E, Lubetzki C, Bensa C, Gout O, Giannesini C, Stankoff B, Ciron J, Brassat D, Pelletier J, Rico Lamy A, Audoin B; SFSEP and OFSEP groups.

Mult Scler. 2018 May 1:1352458518772748. doi: 10.1177/1352458518772748. [Epub ahead of print]

PMID:
29722639
16.

Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.

Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, Ciron J, Collongues N, Brassat D, Cotton F, Papeix C, Durand-Dubief F, Laplaud D, Deschamps R, Cohen M, Biotti D, Ayrignac X, Tilikete C, Thouvenot E, Brochet B, Dulau C, Moreau T, Tourbah A, Lebranchu P, Michel L, Lebrun-Frenay C, Montcuquet A, Mathey G, Debouverie M, Pelletier J, Labauge P, Derache N, Coustans M, Rollot F, De Seze J, Vukusic S, Marignier R; OFSEP and NOMADMUS Study Group.

Neurology. 2018 May 22;90(21):e1858-e1869. doi: 10.1212/WNL.0000000000005560. Epub 2018 Apr 25.

PMID:
29695592
17.

Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders

Ciron J, Audoin B, Bourre B, Brassat D, Durand-Dubief F, Laplaud D, Maillart E, Papeix C, Vukusic S, Zephir H, Marignier R, Collongues N; NOMADMUS group, under the aegis of OFSEP, SFSEP.

Rev Neurol (Paris). 2018 Apr;174(4):255-264. doi: 10.1016/j.neurol.2017.11.005. Epub 2018 Mar 30. Review.

PMID:
29606320
18.

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA.

Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. Review.

PMID:
29275977
19.

Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?

Rouzaud C, Hautecoeur P, Donze C, Heinzlef O, Dinh A; Club Francophone de la Sclérose en Plaque, Creange A, Abdullatif A, Audouin B, Tourbah A, Berger E, Bourre B, Brochet B, Mekies C, Cabre P, Papeix C, Casez O, Brassat D, Defer G, Derache N, De Seze J, Dive D, LePage E, Fromont A, Gouider R, Edan G, Pelletier J, Grimaud J, Guennoc AM, Camdessanché JP, Kwiatkowski A, Laplaud D, Lebrun C, Debouverie M, Coustans M, Gout O, La Rochelle OA, Heinzlef O, Ouallet JC, Cavelou P, Hautecoeur P, Labauge P, Vermersch P, Wiertlewski S, Vukusic S, Marignier R, Schluep M, Seeldrayers P, Slassi I, Stankoff B, Thaite F, Moreau T, Thouvenot E, Zephir H, Ciron J, Collongues N, Kerschen P, Cohen M, Gueguen A, Mathey G, Carra C, Bernady P, Faucheux JM, Planque E, Donze C, Ruet A, Mouzawakh C, Pittion S.

Mult Scler Relat Disord. 2017 Nov;18:161-163. doi: 10.1016/j.msard.2017.08.009. Epub 2017 Aug 24. No abstract available.

PMID:
29141801
20.

Weekly follow up of acute lesions in three early multiple sclerosis patients using MR spectroscopy and diffusion.

Kocevar G, Stamile C, Hannoun S, Roch JA, Durand-Dubief F, Vukusic S, Cotton F, Sappey-Marinier D.

J Neuroradiol. 2018 Mar;45(2):108-113. doi: 10.1016/j.neurad.2017.06.010. Epub 2017 Oct 13.

PMID:
29032126
21.

Isolated positive anti-SS-B autoantibodies are not related to clinical features of systemic autoimmune diseases: Results from a routine population survey.

Jardel S, Fabien N, Hot A, Vukusic S, Tebib J, Cottin V, Sève P, Laville M, Belot A, Durieu I, Garnier L, Coutant F, Reynaud Q, Lega JC.

PLoS One. 2017 Sep 20;12(9):e0185104. doi: 10.1371/journal.pone.0185104. eCollection 2017.

22.

MOG antibody-related disorders: common features and uncommon presentations.

Cobo-Calvo Á, Ruiz A, D'Indy H, Poulat AL, Carneiro M, Philippe N, Durand-Dubief F, Deiva K, Vukusic S, Desportes V, Marignier R.

J Neurol. 2017 Sep;264(9):1945-1955. doi: 10.1007/s00415-017-8583-z. Epub 2017 Aug 2.

PMID:
28770374
23.

Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy.

Fissolo N, Pignolet B, Matute-Blanch C, Triviño JC, Miró B, Mota M, Perez-Hoyos S, Sanchez A, Vermersch P, Ruet A, de Sèze J, Labauge P, Vukusic S, Papeix C, Almoyna L, Tourbah A, Clavelou P, Moreau T, Pelletier J, Lebrun-Frenay C, Montalban X, Brassat D, Comabella M; Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment (BIONAT), Best EScalation Treatment in Multiple Sclerosis (BEST-MS), and the Société Francophone de la Sclérose En Plaques (SFSEP) Network.

Ann Neurol. 2017 Aug;82(2):186-195. doi: 10.1002/ana.24987. Epub 2017 Jul 22.

PMID:
28681388
24.

Electrophysiological Correlates of Subliminal Perception of Facial Expressions in Individuals with Autistic Traits: A Backward Masking Study.

Vukusic S, Ciorciari J, Crewther DP.

Front Hum Neurosci. 2017 May 23;11:256. doi: 10.3389/fnhum.2017.00256. eCollection 2017.

25.

Methylprednisolone liver toxicity: A new case and a French regional pharmacovigilance survey.

Dumortier J, Cottin J, Lavie C, Guillaud O, Hervieu V, Chambon-Augoyard C, Scoazec JY, Vukusic S, Vial T.

Clin Res Hepatol Gastroenterol. 2017 Sep;41(4):497-501. doi: 10.1016/j.clinre.2017.03.008. Epub 2017 Apr 21.

PMID:
28438569
26.

Multiple sclerosis broke my heart.

Androdias G, Bernard E, Biotti D, Collongues N, Durand-Dubief F, Pique J, Sanchez I, Delmas C, Ninet J, Marignier R, Vukusic S.

Ann Neurol. 2017 May;81(5):754-758. doi: 10.1002/ana.24935. Epub 2017 May 9.

PMID:
28437859
27.

Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: A multicenter study of 132 patients.

Jamilloux Y, Cohen-Aubart F, Chapelon-Abric C, Maucort-Boulch D, Marquet A, Pérard L, Bouillet L, Deroux A, Abad S, Bielefeld P, Bouvry D, André M, Noel N, Bienvenu B, Proux A, Vukusic S, Bodaghi B, Sarrot-Reynauld F, Iwaz J, Amoura Z, Broussolle C, Cacoub P, Saadoun D, Valeyre D, Sève P; Groupe Sarcoïdose Francophone.

Semin Arthritis Rheum. 2017 Oct;47(2):288-294. doi: 10.1016/j.semarthrit.2017.03.005. Epub 2017 Mar 8.

PMID:
28392046
28.

Primary and secondary progressive MS have a similar age at onset of progression - YES.

Vukusic S.

Mult Scler. 2017 Apr;23(5):638-639. doi: 10.1177/1352458517690273. No abstract available.

PMID:
28357926
29.

Neuromyelitis optica and neuromyelitis optica spectrum disorders.

Marignier R, Cobo Calvo A, Vukusic S.

Curr Opin Neurol. 2017 Jun;30(3):208-215. doi: 10.1097/WCO.0000000000000455. Review.

PMID:
28306572
30.

Geographical Heterogeneity of Multiple Sclerosis Prevalence in France.

Pivot D, Debouverie M, Grzebyk M, Brassat D, Clanet M, Clavelou P, Confavreux C, Edan G, Leray E, Moreau T, Vukusic S, Hédelin G, Guillemin F.

PLoS One. 2016 Dec 9;11(12):e0167556. doi: 10.1371/journal.pone.0167556. eCollection 2016.

31.

Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.

Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, Bourre B, Brochet B, Camdessanche JP, Labauge P, Moreau T, Brassat D, Stankoff B, de Seze J, Vukusic S, Marignier R; NOMADMUS study group and the Observatoire Français de la Sclérose en Plaques (OFSEP).

Mult Scler. 2017 Sep;23(10):1377-1384. doi: 10.1177/1352458516678474. Epub 2016 Nov 25.

PMID:
27885065
32.

Risk of relapse after natalizumab withdrawal: Results from the French TYSEDMUS cohort.

Papeix C, Vukusic S, Casey R, Debard N, Stankoff B, Mrejen S, Uhry Z, Van Ganse E, Castot A, Clanet M, Lubetzki C, Confavreux C; TYSEDMUS and OFSEP Group.

Neurol Neuroimmunol Neuroinflamm. 2016 Oct 28;3(6):e297. eCollection 2016 Dec.

33.

Graph Theory-Based Brain Connectivity for Automatic Classification of Multiple Sclerosis Clinical Courses.

Kocevar G, Stamile C, Hannoun S, Cotton F, Vukusic S, Durand-Dubief F, Sappey-Marinier D.

Front Neurosci. 2016 Oct 25;10:478. eCollection 2016.

34.

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.

Pignolet B, Schwab N, Schneider-Hohendorf T, Bucciarelli F, Biotti D, Averseng-Peaureaux D, Outteryck O, Ongagna JC, de Sèze J, Brochet B, Ouallet JC, Debouverie M, Pittion S, Defer G, Derache N, Hautecoeur P, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Berger E, Pelletier J, Rico A, Zéphir H, Laplaud D, Wiertlewski S, Camu W, Thouvenot E, Casez O, Moreau T, Fromont A, Vukusic S, Papeix C, Vermersch P, Comabella M, Lebrun-Frenay C, Wiendl H, Brassat D; BIONAT, SFSEP, and BEST-MS networks.

Neurology. 2016 Dec 6;87(23):2491-2494. Epub 2016 Nov 4. No abstract available.

PMID:
27815407
35.

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.

Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, De Sèze J, Debouverie M, Gout O, Clavelou P, Defer G, Laplaud DA, Moreau T, Labauge P, Brochet B, Sedel F, Pelletier J; MS-SPI study group.

Mult Scler. 2016 Nov;22(13):1719-1731. Epub 2016 Sep 1.

36.

Rituximab versus fingolimod after natalizumab in multiple sclerosis: Also consider progressive multifocal leukoencephalopathy risk.

Marignier R, Durand-Dubief F, du Pasquier R, Vukusic S.

Ann Neurol. 2016 Nov;80(5):791. doi: 10.1002/ana.24768. Epub 2016 Sep 15. No abstract available.

PMID:
27554031
37.

History of multiple sclerosis in 2 successive pregnancies: A French and Italian cohort.

Benoit A, Durand-Dubief F, Amato MP, Portaccio E, Casey R, Roggerone S, Androdias G, Gignoux L, Ionescu I, Marrosu MG, Cocco E, Ghezzi A, Annovazzi P, Trojano M, Simone M, Marignier R, Confavreux C, Vukusic S.

Neurology. 2016 Sep 27;87(13):1360-7. doi: 10.1212/WNL.0000000000003036. Epub 2016 Jul 27.

PMID:
27466470
38.

Progressive multifocal leukoencephalopathy after liver transplantation can have favorable or unfavorable outcome.

Dumortier J, Guillaud O, Bosch A, Coppéré B, Petiot P, Roggerone S, Vukusic S, Boillot O.

Transpl Infect Dis. 2016 Aug;18(4):606-10. doi: 10.1111/tid.12554. Epub 2016 Aug 2.

PMID:
27224849
39.

Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid.

Marignier R, Ruiz A, Cavagna S, Nicole A, Watrin C, Touret M, Parrot S, Malleret G, Peyron C, Benetollo C, Auvergnon N, Vukusic S, Giraudon P.

J Neuroinflammation. 2016 May 18;13(1):111. doi: 10.1186/s12974-016-0577-8.

40.

A rare case of SPG11 mutation with multiple sclerosis.

Laurencin C, Rascle L, Cotton F, Grosset-Janin C, Bernard E, Depienne C, Vukusic S, Thobois S.

Rev Neurol (Paris). 2016 Jun-Jul;172(6-7):389-91. doi: 10.1016/j.neurol.2016.03.006. Epub 2016 May 11.

PMID:
27180005
41.

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.

Barbin L, Rousseau C, Jousset N, Casey R, Debouverie M, Vukusic S, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Créange A, Labauge P, Magy L, Defer G, Foucher Y, Laplaud DA; CFSEP and OFSEP groups.

Neurology. 2016 Feb 23;86(8):771-8. doi: 10.1212/WNL.0000000000002395. Epub 2016 Jan 29.

42.

[Epidemiology of multiple sclerosis and new diagnostic criteria].

Leray E, Vukusic S.

Rev Prat. 2016 Jan;66(1):32-36. French.

PMID:
30512395
43.

Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes.

Juryńczyk M, Weinshenker B, Akman-Demir G, Asgari N, Barnes D, Boggild M, Chaudhuri A, D'hooghe M, Evangelou N, Geraldes R, Illes Z, Jacob A, Kim HJ, Kleiter I, Levy M, Marignier R, McGuigan C, Murray K, Nakashima I, Pandit L, Paul F, Pittock S, Selmaj K, de Sèze J, Siva A, Tanasescu R, Vukusic S, Wingerchuk D, Wren D, Leite I, Palace J.

J Neurol. 2016 Jan;263(1):140-9. doi: 10.1007/s00415-015-7952-8. Epub 2015 Nov 3.

44.

Antibodies to aquaporin-1 are not present in neuromyelitis optica.

Schanda K, Waters P, Holzer H, Aboulenein-Djamshidian F, Leite MI, Palace J, Vukusic S, Marignier R, Berger T, Reindl M.

Neurol Neuroimmunol Neuroinflamm. 2015 Oct 1;2(6):e160. doi: 10.1212/NXI.0000000000000160. eCollection 2015 Dec. No abstract available.

45.

Peripheral small fiber dysfunction and neuropathic pain in patients with Morvan syndrome.

Laurencin C, André-Obadia N, Camdessanché JP, Mauguière F, Ong E, Vukusic S, Peter-Derex L, Meyronet D, Bouhour F, Vial C, Ducray F, Honnorat J, Petiot P.

Neurology. 2015 Dec 8;85(23):2076-8. doi: 10.1212/WNL.0000000000002037. Epub 2015 Sep 23. No abstract available.

PMID:
26400578
46.

Multiple sclerosis lesion formation and early evolution revisited: A weekly high-resolution magnetic resonance imaging study.

Guttmann CR, Rousset M, Roch JA, Hannoun S, Durand-Dubief F, Belaroussi B, Cavallari M, Rabilloud M, Sappey-Marinier D, Vukusic S, Cotton F.

Mult Scler. 2016 May;22(6):761-9. doi: 10.1177/1352458515600247. Epub 2015 Sep 11.

PMID:
26362901
47.

Efficacy of rituximab in refractory neuromyelitis optica.

Collongues N, Brassat D, Maillart E, Labauge P, Ouallet JC, Carra-Dalliere C, Moreau T, Bourre B, Papeix C, Brochet B, Audoin B, Vukusic S, de Seze J, Marignier R; OFSEP and CFSEP.

Mult Scler. 2016 Jun;22(7):955-9. doi: 10.1177/1352458515602337. Epub 2015 Sep 11.

PMID:
26362900
48.

Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study.

Leray E, Vukusic S, Debouverie M, Clanet M, Brochet B, de Sèze J, Zéphir H, Defer G, Lebrun-Frenay C, Moreau T, Clavelou P, Pelletier J, Berger E, Cabre P, Camdessanché JP, Kalson-Ray S, Confavreux C, Edan G.

PLoS One. 2015 Jul 6;10(7):e0132033. doi: 10.1371/journal.pone.0132033. eCollection 2015.

49.

Multiple sclerosis and pregnancy in the 'treatment era'.

Vukusic S, Marignier R.

Nat Rev Neurol. 2015 May;11(5):280-9. doi: 10.1038/nrneurol.2015.53. Epub 2015 Apr 21. Review.

PMID:
25896084
50.

Neuromyelitis optica: a positive appraisal of seronegative cases.

Bernard-Valnet R, Liblau RS, Vukusic S, Marignier R.

Eur J Neurol. 2015 Dec;22(12):1511-8, e82-3. doi: 10.1111/ene.12679. Epub 2015 Feb 16. Review.

PMID:
25689634

Supplemental Content

Loading ...
Support Center